WO2008144590A3 - Long lasting modified antifusogenic peptide for preventing hiv infection - Google Patents

Long lasting modified antifusogenic peptide for preventing hiv infection Download PDF

Info

Publication number
WO2008144590A3
WO2008144590A3 PCT/US2008/064016 US2008064016W WO2008144590A3 WO 2008144590 A3 WO2008144590 A3 WO 2008144590A3 US 2008064016 W US2008064016 W US 2008064016W WO 2008144590 A3 WO2008144590 A3 WO 2008144590A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
hiv infection
long lasting
preventing hiv
antifusogenic peptide
Prior art date
Application number
PCT/US2008/064016
Other languages
French (fr)
Other versions
WO2008144590A2 (en
Inventor
Omar Quraishi
Cheryl A Stoddard
Paul Black
Original Assignee
Conjuchem Biotechnologies Inc
Us Gov Health & Human Serv
Univ California San Francisco
Omar Quraishi
Cheryl A Stoddard
Paul Black
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc, Us Gov Health & Human Serv, Univ California San Francisco, Omar Quraishi, Cheryl A Stoddard, Paul Black filed Critical Conjuchem Biotechnologies Inc
Publication of WO2008144590A2 publication Critical patent/WO2008144590A2/en
Publication of WO2008144590A3 publication Critical patent/WO2008144590A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
PCT/US2008/064016 2007-05-16 2008-05-16 Long lasting modified antifusogenic peptide for preventing hiv infection WO2008144590A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93840307P 2007-05-16 2007-05-16
US60/938,403 2007-05-16

Publications (2)

Publication Number Publication Date
WO2008144590A2 WO2008144590A2 (en) 2008-11-27
WO2008144590A3 true WO2008144590A3 (en) 2009-01-22

Family

ID=39820961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064016 WO2008144590A2 (en) 2007-05-16 2008-05-16 Long lasting modified antifusogenic peptide for preventing hiv infection

Country Status (1)

Country Link
WO (1) WO2008144590A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303245B (en) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 Anti-syncytial virus membrane fusion inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2002096935A2 (en) * 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
WO2004029201A2 (en) * 2002-09-24 2004-04-08 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2002096935A2 (en) * 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
WO2004029201A2 (en) * 2002-09-24 2004-04-08 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STODDART ET AL.: "Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and t-20 in vitro with sustained activity in SCID-HU Thy/Liv mice", JOURNAL OF BIOLOGICAL CHEMISTRY, 22 September 2008 (2008-09-22), XP002500131, Retrieved from the Internet <URL:http://www.jbc.org/cgi/reprint/M805536200v1> [retrieved on 20081016] *

Also Published As

Publication number Publication date
WO2008144590A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2002096935A3 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
WO2009129470A3 (en) Methods for treating herpes virus infections
WO2009032123A3 (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections
MX2010005355A (en) 3-aminosulfonyl substituted indole derivatives and methods of use thereof.
MX2010002318A (en) 2,3-substituted azaindole derivatives for treating viral infections.
WO2008118849A3 (en) Hiv-1 protease inhibitors
MX2010002317A (en) Substituted indole derivatives and methods of use thereof.
WO2011123645A3 (en) Nucleoside phosphoramidates
EA201301158A1 (en) ANTI-VIRUS COMPOUNDS
EP2853531A3 (en) Antiviral compounds
WO2008133753A3 (en) Anti-viral compounds
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
WO2009094190A3 (en) Methods of treating viral infections
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
WO2011130557A3 (en) Phosphonates with reduced toxicity for treatment of viral infections
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
CR7806A (en) INHIBITORS OF THE FUSION OF PEPTIDE DERIVATIVES OF HIV INFECTION
WO2020252441A3 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
WO2010138419A3 (en) Materials and methods for treating viral infections
WO2008064072A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
WO2008045017A3 (en) Sars and ebola inhibitors and use thereof, and methods for their discovery
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
WO2007002172A3 (en) Hiv-1 protease inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755798

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08755798

Country of ref document: EP

Kind code of ref document: A2